Moderna (MRNA) Revenue — Quarter Ended Dec 31, 2025
Revenue for the reported quarter declined sharply compared with both the immediately preceding quarter and the same quarter one year earlier. The sequential drop and the year-over-year decrease were both significant.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue for the reported quarter declined sharply compared with both the immediately preceding quarter and the same quarter one year earlier. The sequential drop and the year-over-year decrease were both significant.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$678M
Revenue reported for this quarter.
Quarter-over-quarter
-33.3%
Change from the immediately preceding quarter.
Year-over-year
-29.8%
Change from the comparable year-ago quarter.
Trailing four quarters
$1.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $108M | -35.3% |
| Jun 30, 2025 | $142M | -41.1% |
| Sep 30, 2025 | $1B | -45.4% |
| Dec 31, 2025 | $678M | -29.8% |
Revenue performance
The reported revenue moved lower, reflecting a continued downward trend from the prior quarter.
Quarterly comparison
Revenue was lower than in the immediately preceding quarter and also lower than in the same quarter one year earlier.
What to watch
The persistent year-over-year decline in quarterly revenue may warrant attention to future revenue trends.